RT Journal Article
T1 Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
A1 Ampuero, Javier
A1 Reddy, K Rajender
A1 Romero-Gomez, Manuel
K1 Daclatasvir
K1 Genotype 3
K1 Hepatitis C
K1 Ledipasvir
K1 Sofosbuvir
AB To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies. (1) PEG-INF-based therapy including sofosbuvir (SOF) + RBV for 12 wk vs SOF + RBV 24 wk; (2) SOF + RBV therapy 12 wk/16 wk vs 24 wk; and (3) the role of RBV in SOF + daclatasvir (DCV) and SOF + ledipasvir (LDV) combinations. This meta-analysis provides robust information with the intention of addressing treatment strategy for hepatitis C virus genotype 3. A combination treatment including SOF + RBV + PEG-IFN for 12 wk notes better SVR than with only SOF + RBV for 12 wk, although its association with more frequent adverse effects may be a limiting factor. Longer duration therapy with SOF + RBV (24 wk) has achieved higher SVR rates than shorter durations (12 or 16 wk). SOF + LDV are not an ideal treatment for genotype 3. Lastly, SOF + DCV combination is probably the best oral therapy option and the addition of RBV does not appear to be needed to increase SVR rates substantially.
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10175
UL http://hdl.handle.net/10668/10175
LA en
DS RISalud
RD Apr 17, 2025